Cited by 303Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

Le, Michael H., Le, David M., Baez, Thomas C., Wu, Yuankai, Ito, Takanori, Lee, Eunice Y., Lee, KeeSeok, Stave, Christopher D., Henry, Linda, Barnett, Scott D., Cheung, Ramsey, Nguyen, Mindie H.·2023·Journal of Hepatology

DOI 10.1016/j.jhep.2023.03.040

Open this paper in CoChat — free account

Abstract

Background & aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. We aimed to estimate the pooled global NAFLD incidence.Methods We performed a systematic review and meta-analysis of cohort studies of adults without NAFLD at baseline to evaluate the global incidence of ultrasound-diagnosed NAFLD.Results A total of 63 eligible studies (1,201,807 persons) were analyzed. Studies were from Mainland China/Hong Kong (n = 26), South Korea (n = 22), Japan (n = 14), other (n = 2, Sri Lanka, Israel); 63.8% were clinical center studies; median study year 2000 to 2016; 87% were good quality. Among the 1,201,807 persons at risk, 242,568 persons developed NAFLD, with an incidence rate of 4,612.8 (95% CI 3,931.5-5,294.2) per 100,000 person-years and no statistically significant differences by study sample size (p = 0.90) or study setting (p = 0.055). Males had higher incidence vs. females (5,943.8 vs. 3,671.7, p = 0.0013). Both the obese (vs. non-obese) and the overweight/obese groups (vs. normal weight) were about threefold more likely to develop NAFLD (8,669.6 vs. 2,963.9 and 8,416.6 vs. 3,358.2, respectively) (both p <0.0001). Smokers had higher incidence than non-smokers (8,043.2 vs. 4,689.7, p = 0.046). By meta-regression, adjusting for study year, study setting, and study location, study period of 2010 or after and study setting were associated with increased incidence (p = 0.010 and p = 0.055, respectively). By country, China had a higher NAFLD incidence compared to non-China regions (p = 0.012) and Japan a lower incidence compared to non-Japan regions (p = 0.005).Conclusions NAFLD incidence is increasing with a current estimate of 4,613 new cases per 100,000 person-years. Males and overweight/obese individuals had significantly higher incidence rates compared to females and those of normal weight. Public health interventions for prevention of NAFLD are needed with a special emphasis on males, overweight/obese individuals, and higher risk regions.Impact and implications Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of people worldwide and appears to be increasing, but data to estimate the incidence rate are limited. In this meta-analytic study of over 1.2 million people, we estimated an incidence rate of NAFLD of 46.13 per 1,000 person-years with significant differences by sex, BMI, geography, and time-period. As treatment options for NAFLD remain limited, prevention of NAFLD should remain the focus of public health strategies. Studies such as these can help policy makers in determining which and whether their interventions are impactful.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.03.040

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Untitled work
(2014) · Medical Entomology and Zoology · Cited by 17,633
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citation
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method
IntHout, J., Ioannidis, J. P., & Borm, G. F. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-25 · Cited by 2,419
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925

Show all 51 references

Sorted by citations

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
“[ 37] The incidence rate was also found to be higher in smokers versus non smokes, those obese or overweight compared to normal weight, while China had the highest incidence rates compared to non-China areas and Japan had the lowest incidence rates.”
Background
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Global burden of metabolic diseases, 1990–2021
Zhang, H., Zhou, X., Shapiro, M. D., Lip, G. Y. H., Tilg, H., Valenti, L. V. C., Somers, V. K., Byrne, C. D., Targher, G., Yang, W., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155999 · Cited by 382
Steatotic liver disease
Israelsen, M. E., Francque, S., Tsochatzis, E. A., & Krag, A. A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 381
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
“MASLD incidence was higher in men than women (5,944 per 100,000 person-years versus 3,672 per 100,000 person-years, P 0.0001) 26 .”
Influential
Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis, V., & Papatheodoridis, G. (2023) · European journal of internal medicine · doi:10.1016/j.ejim.2023.11.005 · Cited by 222
Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations
Ni, Y., Qian, L., Siliceo, S. L., Long, X., Nychas, E., Liu, Y., Ismaiah, M. J., Leung, H., Zhang, L., Gao, Q., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.002 · Cited by 237
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1433857 · Cited by 235
“%) with impaired insulin response, type 2 diabetes, dyslipidaemia, hypertriglyceridemia, hypertension, and more than 90% of obese patients with type 2 diabetes have MASH (Le et al., 2023).”
BackgroundInfluential
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024
Peery, A. F., Murphy, C. C., Anderson, C., Jensen, E. T., Deutsch‐Link, S., Egberg, M. D., Lund, J. L., Subramaniam, D., Dellon, E. S., Sperber, A. D., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2024.12.029 · Cited by 117
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Ratziu, V., Hompesch, M., Petitjean, M., Serdjebi, C., Iyer, J. S., Parwani, A. V., Tai, D., Bugianesi, E., Cusi, K. J., Friedman, S. L., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.015 · Cited by 103
Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
Oñate, F. P., Chamignon, C., Burz, S. D., Lapaque, N., Monnoye, M., Philippe, C., Bredel, M., Chêne, L., Farin, W., Paillarse, J.-M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512232 · Cited by 97
“NAFLD, which is the hepatic manifestation of the metabolic syndrome, is the leading cause of chronic liver diseases in Western countries as well as in other regions, with a prevalence as high as 30% in the general population [1] and an increasing incidence [2].”
Background
Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040
Qiu, S., Cai, J., Yang, Z., He, X., Xing, Z., Zu, J., Xie, E., Henry, L. L., Chong, C. R., John, E. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.45525 · Cited by 104
Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States
Xuan, Y., Wu, D., Zhang, Q., Yu, Z., Yu, J., & Zhou, D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1457598 · Cited by 90
“(4).”
The global burden of fatty liver disease: the major impact of China
Lou, T.-W., Yang, R., & Fan, J. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-556 · Cited by 84
“A systematic review and meta-analysis by Le et al. (6) reported that the pooled incidence of NAFLD in Asian adults was 46.13/1,000 person-years (95% CI: 39.32–52.94); the incidence of NAFLD in men was significantly higher than that in women (53.10 vs. 33.70/1,000 person-years); the risk of NAFLD in…”
BackgroundInfluential
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Fan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 92
Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development
Wang, L., Yan, Y., Wu, L., & Peng, J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106925 · Cited by 79
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective
Younossi, Z. M., Razavi, H. A., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K. J., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70020 · Cited by 68
“The prevalence is continuing to increase at an alarming rate [14, 16] leading to a growing overall burden of disease.”
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
de Souza, M. H. G., Diaz, I., Barchetta, I., & Mantovani, A. (2023) · Liver International · doi:10.1111/liv.15763 · Cited by 62
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review
Ghazanfar, H., Javed, N., Qasim, A., Zacharia, G. S., Ghazanfar, A., Jyala, A., Shehi, E., & Patel, H. (2024) · Cancers · doi:10.3390/cancers16061214 · Cited by 50
The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health
Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 61
“It is characterized by the presence of steatosis in no less than 5% of hepatocytes which can progress to inflammation and fibrosis leading to metabolic dysfunction-associated steatohepatitis (MASH) and liver cirrhosis [3,4,23,24].”
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Mao, X., Zhang, X., Kam, L. Y., Chien, N., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2024) · Gut · doi:10.1136/gutjnl-2024-332481 · Cited by 44
A public health perspective on mitigating the global burden of chronic liver disease
Balakrishnan, M., & Rehm, J. T. (2023) · Hepatology · doi:10.1097/hep.0000000000000679 · Cited by 41
“The risk of developing MASLD increases 3-fold among adults with a body mass index of 25 kg/m 2 (23 kg/m 2 among Asian populations) and above, [9] with dose-dependent increases seen with every per unit increase in waist circumference and body mass index.”
Background
Inappropriate Diet Exacerbates Metabolic Dysfunction-Associated Steatotic Liver Disease via Abdominal Obesity
Xiang, M., Tian, X., Wang, H., Gan, P., & Zhang, Q. (2024) · Nutrients · doi:10.3390/nu16234208 · Cited by 40
Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future
Dong, X., Li, J.-M., Lü, X., Lin, X.-Y., Hong, M., Weng, S., & Pan, J. (2024) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-23-118 · Cited by 38
Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model
Chu, X., Wang, X., Feng, K., Bi, Y., Xin, Y., & Liu, S. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02483-z · Cited by 44
“The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased from 25 to 38% over the past 30 years [1–3].”
The burden of liver disease in Latin America
Díaz, L. A., Villota‐Rivas, M., Francisco Barrera, M., Lazarus, J. V., & Arrese, M. A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101175 · Cited by 42
Trimethylamine N-oxide, choline and its metabolites are associated with the risk of non-alcoholic fatty liver disease
Ma, R., Shi, G.-Y., Li, Y., & Shi, H. (2024) · British Journal Of Nutrition · doi:10.1017/s0007114524000631 · Cited by 37
“Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent hepatic disorder worldwide and is estimated to afflict approximately 38 % of the world ’ s population, with an annual incidence of 46 · 13 new cases per 1000 person-years (1,2) .”
Background
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals
de Souza, M. H. G., Diaz, I., & Al‐Sharif, L. (2024) · Hepatology International · doi:10.1007/s12072-024-10716-z · Cited by 37
“Its prevalence is increasing in parallel with the global obesity epidemic, resulting in a significant social and economic burden [2].”
Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
Zou, H., Ma, X., Pan, W. Q., & Xie, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1411802 · Cited by 41
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34
“The prevalence of NASH ranges from ~2% to 6.5% globally, with a nearly two-fold increase among high-risk individuals such as middle-aged individuals in the USA [25].”
BackgroundInfluential
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Zhang, H., Targher, G., Byrne, C. D., Kim, S., Wong, V. W.-S., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C. S., Crespo, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10702-5 · Cited by 34
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad, F. M., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13793 · Cited by 38
“Prospective data indicated a 14% prevalence of advanced ﬁbrosis and a 6% prevalence of cirrhosis in patients with T2DM [8].”
Background
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040
Zhang, X., Linden, S., Levesley, C. R., He, X., Yang, Z., Barnet, S., Cheung, R. C., Ji, F., & Nguyen, M. H. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.16367 · Cited by 33
The newly proposed Metabolic Score for Visceral Fat is a reliable tool for identifying non-alcoholic fatty liver disease, requiring attention to age-specific effects in both sexes
Kuang, M., Qiu, J., Li, D., Hu, C., Zhang, S., Sheng, G., & Zou, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1281524 · Cited by 31
The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Lonardo, A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2259306 · Cited by 29
“…persons and 63 eligible studies found that NAFLD incidence is increasing, with a current estimate of 4,613 new cases per 100,000 person-years; however, compared to women and to normal weight individuals, men and overweight/obese individuals had significantly higher disease incidence rates [48].”
Result
Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease
Navarro, P., Gutiérrez‐Ramírez, L., Tejera‐Muñoz, A., Arias, Á., & Lucendo, A. J. (2023) · Nutrients · doi:10.3390/nu15214507 · Cited by 28
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Wang, J., Jiang, S., Hu, A., Zhou, A.-W., Hu, T., Li, H., Fan, Y., & Lin, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27325 · Cited by 28
“Of note, the aging of the population, as well as the growing obesity and diabetes epidemic, will probably have a significant impact on its prevalence in the years to come [11 – 13].”
Background
Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models
Wang, Y., Zhou, J., Yang, Q., Li, X., Qiu, Y., Zhang, Y., Liu, M., & Zhu, A. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100635 · Cited by 28
Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD
Pustjens, J., van Kleef, L. A., Janssen, H. L. A., de Knegt, R. J., & Brouwer, W. P. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101193 · Cited by 29
Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
Jamil, A., Chivese, T., Elshaikh, U. A. M., & Sendall, M. C. (2024) · BMC Public Health · doi:10.1186/s12889-024-19378-w · Cited by 26
“The prevalence of MASLD has increased over recent years from 2000 per 100,000 person-years in the year 2000 to 7000 per 100,000 in the year 2015 [2].”
Background
Regular exercise alleviates metabolic dysfunction-associated steatohepatitis through rescuing mitochondrial oxidative stress and dysfunction in liver
Lin, B., Wu, T., Nasb, M., Li, Z., & Chen, N. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.02.017 · Cited by 26
Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
Jain, P., Jain, A., Deshmukh, R., Samal, P. K., Satapathy, T., & Ajazuddin, M. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102584 · Cited by 26
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
Sun, B., Ding, X., Tan, J., Zhang, J., Chu, X., Zhang, S., Liu, S., Zhao, Z., Xuan, S., Xin, Y., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0268 · Cited by 25
Towards precision medicine in non-alcoholic fatty liver disease
Francque, S. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09820-6 · Cited by 25
“NAFLD also shows marked sex-related differences [37], attributed mainly to the protective actions of oestrogens [38, 39].”
Background
The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: A systematic review and meta-analysis
Pan, K., Xu, J., Xu, Y., Wang, C., & Yu, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107251 · Cited by 26
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Elshaer, A., Chascsa, D. M. H., & Lizaola‐Mayo, B. (2024) · Life · doi:10.3390/life14070844 · Cited by 26
Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes
Wang, S., Lin, X., Zhu, C., Dong, Y., Guo, Y., Xie, Z., He, X., Ju, W., & Chen, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1287916 · Cited by 23
Elevated GGT to HDL ratio as a marker for the risk of NAFLD and liver fibrosis
Xuan, Y., He, F., Liu, Q. F., Dai, D., Wu, D., Shi, Y., & Yao, Q. Z. (2025) · Scientific Reports · doi:10.1038/s41598-024-84649-w · Cited by 25
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial
Hu, Y., Li, H., Zhang, H., Chen, X., Chen, J., Xu, Z., You, H., Dong, R., Peng, Y., Li, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42162-0 · Cited by 23
Sex and gender differences in metabolic dysfunction-associated liver disease
Penmetsa, R., Kapil, S. R., & VanWagner, L. B. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01833-0 · Cited by 21
Adrenic acid: A promising biomarker and therapeutic target (Review)
Wang, Z., Gao, H., Ma, X., Zhu, D., Zhao, L., & Xiao, W. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5461 · Cited by 21
“Approximately 30% of the global population is estimated to suffer from NAFLd, and this percentage is increasing (42).”
Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries
Younossi, Z. M., Paik, J. M., Lazarus, J. V., Burra, P., Eguchi, Y., Tacke, F., Crespo, J., Villela‐Nogueira, C. A., Brennan, P., Al‐Omar, H. A., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.09.002 · Cited by 22
State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy
Zhong, X., Lv, M., Ma, M., Huang, Q., Hu, R., Li, J., Yi, J., Sun, J., & Zhou, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115131 · Cited by 20
Associations between exposure to ambient particulate matter and advanced liver fibrosis in Chinese MAFLD patients
Xing, Y., Gao, X., Li, Q., Li, X., Wang, Y., Yang, Y., Yang, S., Lau, P. W. C., Zeng, Q., & Wang, H. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.132501 · Cited by 17
The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes
Lorek, D., Łupina, K., Bisaga, W., Malicki, D., Stępień, W., Kumor, L., & Janczura, J. (2025) · Korean Journal of Family Medicine · doi:10.4082/kjfm.25.0027 · Cited by 17
“A recent systematic review and meta-analysis of 63 studies, primarily conducted in Asian countries (China/Hong Kong, 26; South Korea, 22; Japan, 14; Sri Lanka, 1; Israel, 1) by Le et al. [8] found an incidence rate of 46.13 new cases of MASLD per 1,000 person-years.”
Influential
Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study
Zhang, Y., Li, J., Wang, Z., Chen, J., Zhao, M., Guo, C. X., Wang, T., Li, R., Zhang, H., Ma, X., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156651 · Cited by 16
Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study
Kouvari, M., Valenzuela‐Vallejo, L., Axarloglou, E., Verrastro, O., Papatheodoridis, G., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Liver International · doi:10.1111/liv.15847 · Cited by 16
Lipoprotein Combine Index as a Better Marker for NAFLD Identification Than Traditional Lipid Parameters
Qiu, J., Huang, X., Kuang, M., Yang, R., Li, J., Sheng, G., & Zou, Y. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s462181 · Cited by 18
“3,4 Currently, there are no clinically approved medications specifically for treating NAFLD; However, compelling evidence suggests that changes in diet and lifestyle can effectively prevent NAFLD.”
Background
Hepatocellular Interactions of Potential Nutraceuticals in the Management of Inflammatory NAFLD
Ezhilarasan, D., & Kulanthaivel, L. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4112 · Cited by 17
“The global prevalence of NAFLD was estimated to be 24% in 2018 [9] and current estimates indicate that it has risen to 29% [10].”
Two-Year Mediterranean Diet Intervention Improves Hepatic Health in MASLD Patients
Monserrat-Mesquida, M., Bouzas, C., García, S., Mateos, D., Casares, M., Ugarriza, L., Gómez, C., Sureda, A., & Tur, J. A. (2025) · Foods · doi:10.3390/foods14101736 · Cited by 19
“MASLD is a major cause of chronic liver disease (CLD), impacting approximately 30% of the global adult population, with its prevalence continuing to increase [2].”
Insights into the Activities and Usefulness of Deoxynojirimycin and Morus alba: A Comprehensive Review
Tricase, A. F., Cavalluzzi, M. M., Catalano, A. A., Bellis, M. D., Palma, A. D., Basile, G., Sinicropi, M. S., & Lentini, G. (2025) · Molecules · doi:10.3390/molecules30153213 · Cited by 15
“Non-alcoholic fatty liver disease is one of the most common liver diseases affecting about 25% of the population worldwide [151,152].”
Sex Differences in MASLD After Age 50: Presentation, Diagnosis, and Clinical Implications
Milani, I., Parrotta, M. E., Colangeli, L., Chinucci, M., Palleschi, S., Rossi, B., Sbraccia, P., Mantovani, A., Leonetti, F., Guglielmi, V., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092292 · Cited by 15
“Men consistently exhibit a higher prevalence of MASLD [20–22] across all age groups, whereas in women, the risk increases with age [23], reaching or surpassing that of men after menopause [19,22,24–26].”
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Arvanitakis, K., Papadakos, S. P., Lekakis, V., Koufakis, T., Lempesis, I. G., Papantoniou, E., Kalopitas, G., Georgakopoulou, V., Stergiou, I. Ε., Theocharis, S. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914704 · Cited by 16
“The incidence rate has tripled between 2000 and 2015, with higher rates in men and those who are overweight/obese, emphasizing the need for public health interventions targeting at-risk populations as the prevalence of MAFLD continues to rise [10].”
Background
Metabolic Dysfunction-Associated Steatotic Liver Disease: The Associations between Inflammatory Markers, TLR4, and Cytokines IL-17A/F, and Their Connections to the Degree of Steatosis and the Risk of Fibrosis
Coste, S. C., Orasan, O. H., Cozma, A., Negrean, V., Sitar-Tăut, A., Filip, G. A., Hangan, A. C., Lucaciu, R. L., Iancu, M., & Procopciuc, L. M. (2024) · Biomedicines · doi:10.3390/biomedicines12092144 · Cited by 15
Sex Differences in Adverse Liver and Nonliver Outcomes in Steatotic Liver Disease
Yan, T., Zhang, X., Wong, T., Cheung, R. C., & Nguyen, M. H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.48946 · Cited by 15
Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice
Tao, S.-H., Lei, Y., Tan, Y., Yang, Y.-B., & Xie, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1476419 · Cited by 16
Ideal dietary fiber model: Personalized gut microbiota modulation based on structure-function relationships
Wang, C., Qin, S., Shi, J., Zhu, J., Ju, X., Wang, W., & Yang, L. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124097 · Cited by 14
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14
Functional foods and dietary matrices for metabolic improvement: an integrative review of mechanisms, evidence, and future directions
Rahimah, S., Tallei, T. E., Savitri, M., Yamada, C., Kim, H. J., Choi, M., Park, M. N., Ophinni, Y., & Kim, B. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107240 · Cited by 14
Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease
Ding, Y., Dai, X., Bao, M., Xing, Y., Liu, J., Zhao, S., Liu, E., Yuan, Z., & Bai, L. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12338 · Cited by 12
Gender perspective on the association between liver enzyme markers and non-alcoholic fatty liver disease: insights from the general population
Qiu, J., Kuang, M., He, S., Yu, C., Wang, C., Huang, X., Sheng, G., & Zou, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1302322 · Cited by 13
Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease
Chen, J., Zhou, H., & Liu, K. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.024 · Cited by 13
The association of exposure to polychlorinated biphenyls with lipid profile and liver enzymes in umbilical cord blood samples
Hjazi, A. M., Hsu, C., Al-Attar, W. M., Almajidi, Y. Q., Hussien, B. M., Alzahrani, A. A., Kareem, A. K., Alazbjee, A. A. A., & Meng, X. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2023.141096 · Cited by 13
The newly proposed plasma-glycosylated hemoglobin A1c/High-Density lipoprotein cholesterol ratio serves as a simple and practical indicator for screening metabolic associated fatty liver disease: an observational study based on a physical examination population
He, S., Lu, S., Yu, C., Kuang, M., Qiu, J., Sheng, G., & Zou, Y. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03362-0 · Cited by 12
“According to the latest epidemiological data, the global prevalence of MAFLD is estimated to be around 30% [6], and it appears to be on the rise.”
Background
Lactucin ameliorates FFA-induced steatosis in HepG2 cells by modulating mitochondrial homeostasis through the SIRT1/PGC-1α signaling axis
Lei, Y., Ma, X., Liu, T., Wang, M., Kang, J., Yang, J. Q., & Mi, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39890 · Cited by 13
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial
Meyhöfer, S. M., Cariou, B., Cercato, C., Colhoun, H. M., Deanfield, J. E., Long, M. T., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Plutzky, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04281-1 · Cited by 13
“The global prevalence of MASLD is estimated to be ~30% and has risen in parallel with the global surge in obesity, making it an increasingly recognized health concern 4,5 .”
Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis
Liu, X., Wang, J., Li, M., Qiu, J., Li, X., Qi, L., Liu, J., Liu, P., Xie, G., & Wang, X. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16279 · Cited by 13
High Plant Protein Diet Ameliorated Hepatic Lipid Accumulation Through the Modulation of Gut Microbiota
Zhu, S., Zhao, Y., Liu, L., Xu, Y., Zhu, J., Li, W., Liu, Y., & Xia, M. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300515 · Cited by 12
Exposure to per- and polyfluoroalkyl substances, neonicotinoid insecticides, benzotriazoles and benzothiazoles: Associations with human non-alcoholic fatty liver disease
Qin, R., Zhang, B., Zhu, H., Chen, Y., Song, S., & Zhang, B. (2024) · Environmental Chemistry and Ecotoxicology · doi:10.1016/j.enceco.2024.07.005 · Cited by 12
Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts
Zou, H., Wen, P., & Sun, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1571487 · Cited by 12
The effects of time-restricted eating for patients with nonalcoholic fatty liver disease: a systematic review
Lin, X., Wang, S., & Huang, J. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1307736 · Cited by 12
The impacts of Ramadan fasting for patients with non-alcoholic fatty liver disease (NAFLD): a systematic review
Lin, X., Wu, G., & Huang, J. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1315408 · Cited by 11
The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
Mozaffari, S., Aliari, M., Emamgholipour, S., Hosseini, H., Amirkiasar, P. R., Zare, M., Katsiki, N., Panahi, G., & Sahebkar, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108780 · Cited by 11
Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review
Ahmed, M., & Ahmed, M. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133893 · Cited by 13
Lipidomics reveals the lipid-lowering and hepatoprotective effects of Celosia Semen on high-fat diet-induced NAFLD mice
Zhao, J., Zhou, Q., Liu, K., Li, P., Jiang, Y., & Li, H. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118922 · Cited by 11
Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis
Wang, X., Li, S., & Wang, X.-H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1582861 · Cited by 13
RNF2 Modulates Lipid Metabolism and Inflammation in Alcohol-associated Liver Disease by Interacting with USP7
Qi, Y., Fang, Q., Chen, Z., Chen, L., & Du, J. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.111290 · Cited by 11
“MASLD affects approximately 30% of the global population, with its prevalence steadily increasing [42], which has a broader impact than ALD.”
Olfactomedin 4 deletion exacerbates nonalcoholic fatty liver disease through P62-dependent mitophagy in mice
Chen, S., Wang, X., Liu, Z., Wang, J., Guo, Y., Wang, Q., Huang, H., Li, Y., Yu, C., & Xu, C. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155679 · Cited by 11
The new international nomenclature for steatotic liver disease: One step forward towards enhanced awareness for healthier life
van Erpecum, K. J., van Kleef, L. A., Beuers, U. H., & de Knegt, R. J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.09.006 · Cited by 11
Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Nielsen, S. F. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120551 · Cited by 13
Fructose induces hepatic steatosis in adolescent mice linked to the disorders of lipid metabolism, bile acid metabolism, and autophagy
Deng, S., Ge, Y., Zhai, Z., Liu, H., Zhang, X., Chen, Y., Yang, Y., & Wu, Z. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109635 · Cited by 10
Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease
Miao, T., Lou, X.-Z., Dong, S., Zhang, X., Guan, W., Zhang, Y., Li, L., Yuan, X., Ma, D., & Nan, Y. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s439397 · Cited by 10
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
Rui, F., Garcia, E., Hu, X., Ni, W., Xue, Q. C., Xu, Y., Xu, X., Shi, J., Nguyen, M. H., Cheung, R. C., et al. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13942 · Cited by 9
Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
Felicianna, Lo, E. K. K., Chen, C., Ismaiah, M. J., Zhang, F., Leung, H. K. M., & El-Nezami, H. S. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102059 · Cited by 9
Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018
He, M., Du, X.-J., & Liu, Y.-M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03612-9 · Cited by 9
Ultrasound-derived fat fraction for diagnosing hepatic steatosis: a systematic review and meta-analysis
Verdan, S., Torri, G. B., Marcos, V. N., Moreira, M. H. S., Defante, M. L. R., Fagundes, M. D. C., de Barros, E. M. J., Dias, A. B., Shen, L., & Altmayer, S. (2025) · European Radiology · doi:10.1007/s00330-025-11652-8 · Cited by 11
Glycogenic hepatopathy in a primitive teleost fish model: the inductive effect of high carbohydrate diet and the alleviating role of betaine
Zou, J., Chen, Z., Zheng, F., Cao, X., Zhao, Y., Panserat, S., Gao, J., & Wang, Q. (2025) · Marine Life Science & Technology · doi:10.1007/s42995-025-00301-0 · Cited by 11
“NAFLD incidence is continuously increasing, and epidemiological evidence has indicated the contributing roles of excess carbohydrate consumption in metabolic diseases including type 2 diabetes (T2DM) and NAFLD via increasing lipogenesis (Le et al. 2023).”

Authors: Le, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., Cheung, R., & Nguyen, M. H.
Affiliations: University of Vermont (US)
Burrell College of Osteopathic Medicine (US)
Third Affiliated Hospital of Sun Yat-sen University (CN)
Nagoya University (JP)
Stanford Medicine (US)
Stanford University (US)
VA Palo Alto Health Care System (US)
Corresponding author: Nguyen, Mindie H.
ORCID: Le, Michael H.
Wu, Yuankai
Ito, Takanori
Lee, KeeSeok
Stave, Christopher D.
Henry, Linda
Barnett, Scott D.
Cheung, Ramsey
Nguyen, Mindie H.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2023-08
Volume: 79
Issue: 2
Pages: 287-295
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2023.03.040
OpenAlex: W4362719751
Cited by: 303
References: 51
Citations by year: 2026: 71 · 2025: 98 · 2024: 98 · 2023: 35
FWCI: 11.80
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: NAFLD incidence, global prevalence, ultrasonography, obesity, overweight, smoking, sex differences, China, South Korea, Japan, cohort studies, risk factors, study quality bias, study design bias, publication bias
MeSH terms: Adult, Female, Humans, Male, Obesity, Cohort Studies, Incidence, Overweight, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks